# Carvedilol

Drug · id `cardio:carvedilol` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Coreg

Browse, organ or system: Heart  
Browse, condition area: High blood pressure; Coronary and vascular disease; Heart failure  

## In plain language

Carvedilol is a medicine taken by mouth that the FDA label describes as an alpha-/beta-adrenergic blocking agent. The label read, for Coreg, lists three uses: mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, to increase survival and reduce the risk of hospitalization; reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptoms of heart failure; and essential hypertension.

## Technical summary

RxNorm ingredient 20352; UNII 0K47UL67F2. MeSH descriptor D000077261 is Carvedilol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Waylis Therapeutics LLC label for COREG (carvedilol), application NDA020297, effective 2026-07-31 in openFDA. Coreg CR (carvedilol phosphate extended-release capsules) has its own label, which was not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of carvedilol (Coreg) lists an indication: chronic heart failure, survivors of the acute phase of a myocardial infarction whose left ventricular ejection fraction is 40% or less, essential hypertension

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of COREG (carvedilol), in the Waylis Therapeutics LLC version dated 2026-07-31 in openFDA, lists the medicine for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin; for reducing cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and whose left ventricular ejection fraction is 40% or less, with or without symptomatic heart failure; and for the management of essential hypertension.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-08
- Sources:
  1. Supports: openFDA drug label record for COREG (carvedilol), Waylis Therapeutics LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 07c619c6-4a0c-445e-94fa-664a54f68a39 (manufacturer Waylis Therapeutics LLC, application NDA020297), returned on 2026-11-08. The label text is dated 2026-07-31 (effective\_time). Other openFDA records of carvedilol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2207c619c6-4a0c-445e-94fa-664a54f68a39%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1. INDICATIONS AND USAGE. Retrieved 2026-11-08T20:36:57Z. Source state: Current. Version fingerprint: 654e7c2cc0766a1ae7b9072a509447d9ba3519185a297787af7f8e5f1f3b2741.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for COREG (carvedilol), Waylis Therapeutics LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 07c619c6-4a0c-445e-94fa-664a54f68a39 (manufacturer Waylis Therapeutics LLC, application NDA020297), returned on 2026-11-08. The label text is dated 2026-07-31 (effective\_time). Other openFDA records of carvedilol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2207c619c6-4a0c-445e-94fa-664a54f68a39%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-08T20:36:57Z. Source state: Current. Version fingerprint: 654e7c2cc0766a1ae7b9072a509447d9ba3519185a297787af7f8e5f1f3b2741.
     How it applies: Effective date of the label text read, 20260731.

## Connected pages

- Carvedilol is a beta-adrenergic blocker (FDA established pharmacologic class in RxClass): Beta-blockers (drug class) (`cardio:beta-blockers`)
- FDA label lists mild-to-severe chronic heart failure as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-carvedilol-label-indications` and its context]
- FDA label lists reducing cardiovascular mortality after the acute phase of a myocardial infarction, when the left ventricular ejection fraction is 40% or less, as an indication: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-carvedilol-label-indications` and its context]
- FDA label lists essential hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-carvedilol-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 2 registry products
- 10 registry trials

## Provenance

Content hash: 263314c1f56a704cd2b19b752ba8aae69e48e764c5649b869b574116e50ea0ad
Last substantive edit: 2026-11-08
Evidence last checked: 2026-11-08
